Premier Partners Selected as Management Company for K-Bio·Vaccine Fund No. 7
Aiming for 200 Billion Won, Double the Initial Target
Cumulative Total Reaches 779.6 Billion Won
Accelerating Toward 1 Trillion Won Mega Fund Next Year
The Ministry of Health and Welfare announced on June 24 that it has selected Premier Partners as the lead management company for the "K-Bio·Vaccine Fund No. 7," which aims to support the global advancement of the domestic biohealth and vaccine industries.
The ministry explained that, through Korea Venture Investment, it held an open call from March 23 to May 6 of this year. The final management company was chosen after a rigorous process that included document screening, on-site due diligence, and presentation evaluations.
The seventh fund will focus investment on the growth of promising biotech companies, including domestic companies from all fields of biohealth (60%) and companies developing innovative vaccine technologies and manufacturing processes (10%), based on 40 billion won in government contributions (20 billion won from the Ministry of Health and Welfare's budget and 20 billion won from recovered funds). The fund can be formed and begin investing in domestic companies as soon as it raises at least 70% of its initial target, which is 7 billion won or more.
Although the government initially set a formation target of 100 billion won, Premier Partners proposed a fund size of 200 billion won. If the seventh fund achieves its target of 200 billion won, the cumulative amount raised by the K-Bio·Vaccine Funds will reach a total of 779.6 billion won.
The K-Bio·Vaccine Funds No. 1 to No. 6, established since 2023, amount to a total of 579.6 billion won. To date, they have invested 246.3 billion won in 52 companies, including successfully leading three companies with innovative technologies to new listings (IPOs) and achieving other notable results.
The Ministry of Health and Welfare also plans to finalize the selection of a lead management company for a "Phase 3 Clinical Trial Specialized Fund" worth 150 billion won next month and complete its formation within this year. Currently, four asset management companies have applied and are undergoing the review process.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Jeong Eunyoung, Director of the Health Industry Policy Bureau at the Ministry of Health and Welfare, stated, "We hope that the successful formation of the K-Bio·Vaccine Fund No. 7 will invigorate investment in biotech firms and small to mid-sized companies with innovative technologies. Through this, we will actively support the development of new drugs and platform technologies, and we will steadily pursue the creation of a mega fund worth 1 trillion won by 2027, as planned."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.